Jubilant Pharmova Limited has informed the Exchange regarding Notice of Postal Ballot
JUBLPHARMA · price
▲ positive · ▼ negative · ● neutral filings · teal = economic event · numbered = multiple that day (click to pick). Times IST.
Awaiting price reaction for this filing.
Jubilant Pharmova is seeking shareholder approval via postal ballot to sell its Active Pharmaceutical Ingredients (API) business located in Nanjangud, Mysuru (Karnataka) to Jubilant Biosys Limited (JBL), its wholly-owned subsidiary, on a slump sale basis. The transaction is valued at ₹666.50 crores as of March 31, 2025, subject to adjustments based on book value of assets and liabilities as of the appointed date of September 1, 2025. The consideration will be paid not in cash but primarily through the issuance of Optionally Convertible Redeemable Preference Shares (OCRPS) by JBL, with a 10-year tenure, 8% dividend coupon (payable only if dividends are paid), and conversion at NAV. The Board approved the transaction on June 12, 2025, and a Business Transfer Agreement has been executed. The strategic rationale is to combine the API business with JBL's existing Contract Research Organization (CRO) operations to create an integrated Contract Research, Development and Manufacturing Organization (CRDMO) platform. Voting runs from June 25 to July 24, 2025.
This is essentially an internal corporate restructuring between a parent and its wholly-owned subsidiary, so the company states there will be no impact on the economic interest of shareholders or the existing business. The transaction is exempt from related-party shareholder approval because JBL is wholly-owned and its financials are consolidated. Shareholders should note that the API business contributes more than 20% of total income, which is why a Special Resolution under Section 180(1)(a) is being sought. The stock price is unlikely to see a major reaction since it's a value-neutral reorganization, but long-term value depends on the success of the combined CRDMO platform.